VintaBio™ Files Patents for Scalable Manufacturing Platform Built to Accelerate Gene Therapy Commercialization

Audio By Carbonatix

PHILADELPHIA--(BUSINESS WIRE)--Sep 16, 2025--

VintaBio™, a technology-forward company, announced today that it has filed provisional patents with the US Patent Office describing its novel approach to manufacturing biotherapeutics using adherent culturing methods in a small-scale process.

Improving upon the adherent manufacturing approaches used for FDA-approved gene therapies, such as Zolgensma™ and Luxturna™, VintaBio has designed a purpose-built process that reduces large operational footprints that restrict scalability. VintaBio’s process leverages proprietary technology, tools and methods ideally suited for high density culturing of adherent cells in a single-use benchtop bioreactor system. The process eliminates the need for plastic bottles, flasks and other flatware - the result is a high-intensity manufacturing process that delivers the ability to rapidly scale-up in any part of the world.

The first applications for this novel approach have successfully been demonstrated in producing AAV viral vector gene therapies using an HEK293 cell line for clients. Batch data using VintaBio’s process indicates that the percent full capsids generated at harvest is greater than 60% and more than 95% at final purification. The total process recovery rate using VintaBio’s platform is approximately 60%.

The team is currently underway demonstrating proof of concept in other viral vectors including lentivirus, adenovirus and HSV.

Having worked on manufacturing strategies for several other FDA-approved gene therapies, the founders at VintaBio were committed to designing a faster and more scalable manufacturing process for getting therapies to patients. Leveraging their shared experiences and intimate working knowledge of the critical manufacturing challenges, they worked to design a purpose-built process that would alleviate the scalability and productivity limitations of adherently cultured biotherapeutics. Since designing the initial process, VintaBio has continued to build on its working knowledge to further optimize performance and quality through measures such as pooling and perfusion. While successfully executed for AAV gene therapies, the use of VintaBio’s process in vaccines, biotherapeutics and other cell and gene therapies is currently being evaluated.

“The growing interest in our platform is a strong indication that the industry is keen to find better ways to get critical therapies to patients. Not only that, but they also understand that VintaBio fills a critical gap in the current ways of working. Our recent scientific and commercial accomplishments have us poised to take on these challenges and continue to generate strong market demand for other applications – well beyond our initial proof of concept. The applications for our platform are far-reaching and the team at VintaBio is well positioned to get us there,” said David Radspinner, PhD, CEO of VintaBio.

The innovative approach to manufacturing therapeutics developed by VintaBio paves the way for enhanced scalability and a faster path to market for biotherapeutics - reducing the space and equipment demand by 80% and shortening the development time from 18 months to about 3-6 months.

For more information on VintaBio, please visit: www.vintabio.com

About VintaBio:
VintaBio is a technology-forward biomanufacturing company based in Philadelphia, Pennsylvania, focused on accelerating the development and commercialization of gene and cell therapies through a proprietary, scalable manufacturing platform. Founded by industry veterans behind FDA-approved therapies such as Luxturna™ and Zolgensma™, VintaBio addresses one of the most critical challenges in biotherapeutics today: the need for high-quality, efficient, and globally transferable manufacturing solutions.

VintaBio’s innovative approach leverages an intensified perfusion process purpose-built for adherent cell culture, enabling high-density production of viral vectors with significantly reduced space, cost, and timelines. This novel platform cuts development time from 18 months to just 3–6 months, eliminates reliance on traditional plasticware, and is already validated in AAV vector production using HEK293 cells.

The company’s 23,000 sq. ft. Philadelphia facility includes multiple cGMP suites for toxicology and clinical manufacturing, supporting rapid scale-up from early development through commercial readiness.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250916741740/en/

CONTACT: Kiran Chin

Email:[email protected]

www.vintabio.com

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: MEDICAL SUPPLIES BIOTECHNOLOGY MANUFACTURING HEALTH PHARMACEUTICAL RESEARCH GENETICS ENVIRONMENT SCIENCE SUSTAINABILITY CHEMICALS/PLASTICS

SOURCE: VintaBio

Copyright Business Wire 2025.

PUB: 09/16/2025 11:31 AM/DISC: 09/16/2025 11:31 AM

http://www.businesswire.com/news/home/20250916741740/en